Q1 EPS Estimate for Nektar Therapeutics Raised by Analyst

Nektar Therapeutics (NASDAQ:NKTR) – Equities researchers at William Blair upped their Q1 2025 earnings estimates for shares of Nektar Therapeutics in a report issued on Thursday, March 13th. William Blair analyst A. Hsieh now anticipates that the biopharmaceutical company will post earnings per share of ($0.19) for the quarter, up from their previous estimate of ($0.22). William Blair has a “Market Perform” rating on the stock. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.72) per share. William Blair also issued estimates for Nektar Therapeutics’ Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.75) EPS, FY2026 earnings at ($0.87) EPS and FY2027 earnings at ($0.88) EPS.

Nektar Therapeutics (NASDAQ:NKTR) last posted its earnings results on Wednesday, March 12th. The biopharmaceutical company reported $0.15 EPS for the quarter, topping the consensus estimate of ($0.18) by $0.33. Nektar Therapeutics had a negative net margin of 180.70% and a negative return on equity of 173.28%. The company had revenue of $29.18 million during the quarter, compared to the consensus estimate of $36.65 million.

Several other equities research analysts also recently issued reports on NKTR. Oppenheimer upgraded Nektar Therapeutics from a “market perform” rating to an “outperform” rating and set a $6.00 price target for the company in a report on Friday. HC Wainwright reiterated a “buy” rating and issued a $6.50 target price on shares of Nektar Therapeutics in a research note on Thursday, March 13th. Finally, B. Riley initiated coverage on shares of Nektar Therapeutics in a research report on Wednesday, January 8th. They set a “buy” rating and a $4.00 price target on the stock. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $4.92.

Nektar Therapeutics Stock Up 1.4 %

Shares of Nektar Therapeutics stock opened at $0.91 on Monday. Nektar Therapeutics has a 52 week low of $0.65 and a 52 week high of $1.93. The business has a 50 day moving average price of $0.88 and a 200-day moving average price of $1.07. The company has a market cap of $167.73 million, a PE ratio of -1.08 and a beta of 0.65.

Insider Transactions at Nektar Therapeutics

In other Nektar Therapeutics news, insider Mark Andrew Wilson sold 33,402 shares of the company’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $0.90, for a total transaction of $30,061.80. Following the sale, the insider now directly owns 351,892 shares of the company’s stock, valued at $316,702.80. This represents a 8.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Jonathan Zalevsky sold 51,115 shares of the stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $0.94, for a total transaction of $48,048.10. Following the transaction, the insider now owns 326,904 shares of the company’s stock, valued at $307,289.76. This represents a 13.52 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 118,591 shares of company stock worth $112,525 in the last quarter. Insiders own 3.71% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of NKTR. Two Sigma Securities LLC increased its position in shares of Nektar Therapeutics by 56.3% during the fourth quarter. Two Sigma Securities LLC now owns 27,654 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 9,958 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in Nektar Therapeutics by 6.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 192,978 shares of the biopharmaceutical company’s stock worth $180,000 after purchasing an additional 10,941 shares in the last quarter. SG Americas Securities LLC boosted its holdings in Nektar Therapeutics by 12.2% in the 4th quarter. SG Americas Securities LLC now owns 107,318 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 11,681 shares during the period. Northern Trust Corp grew its position in shares of Nektar Therapeutics by 0.9% during the 4th quarter. Northern Trust Corp now owns 1,414,984 shares of the biopharmaceutical company’s stock valued at $1,316,000 after purchasing an additional 12,826 shares in the last quarter. Finally, Moloney Securities Asset Management LLC grew its position in shares of Nektar Therapeutics by 42.4% during the 4th quarter. Moloney Securities Asset Management LLC now owns 50,000 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 14,895 shares in the last quarter. 75.88% of the stock is currently owned by hedge funds and other institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.